ReviewCells2026
Disruption of the Muscle-Brain Axis in Ageing: Role of Myokines in Sarcopenia and Neurodegeneration.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review analyzes how myokines act as key links in communication between skeletal muscle and the brain, focusing on the impact of aging on this axis. Although the current literature links defects in this signaling pathway to sarcopenia, neurodegeneration, and cognitive decline, we still do not know exactly what role each molecule plays individually. Among the main gaps in our understanding are questions about how these substances are transported to the nervous system, what their specific receptors are, and what cause-and-effect relationship actually exists between losing muscle mass and developing neurological problems. In fact, in humans, it remains unclear whether myokines actually reach the brain in truly effective concentrations or whether their benefits are due more to peripheral metabolic, vascular, and inflammatory changes. Today, most of the mechanistic evidence comes from animal and cellular models, while observational studies predominate in humans. This is further complicated by uncertainties regarding the actual origin of these proteins in tissues, their passage through the blood-brain barrier, and their measurement in the blood, making it difficult to determine whether these proteins act as causes, consequences, or simply compensatory responses to aging and disease. On the other hand, although exercise remains the most robust tool for maintaining muscle health and protecting cognitive function, it is still unclear whether we could replicate those same benefits by isolating and stimulating specific myokines. The major challenge for the future is to develop human studies that combine standardized biomarkers with long-term monitoring of muscle function, cognition, and brain structure. Only then will we know whether this fascinating muscle-brain axis can move beyond being a promising hypothesis to become a real therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.